---
figid: PMC6887802__10.1177_1753466619890538-fig3
figlink: /pmc/articles/PMC6887802/figure/fig3-1753466619890538/
number: Figure 3
caption: Lung cancer and autophagy pathway. The blue arrows show the relationships
  between autophagy and occurrence/development of lung cancer. C-K activates mTOR
  through AMPK signal pathway, inactivation of ULKI induced by mTOR increases autophagy
  and participates in the growth and migration of tumor cells. EGFR-TKI involves in
  the development of lung cancer by inhibiting autophagy levels. The yellow arrows
  show that inhibiting autophagy enhances the sensitivity of lung cancer to chemotherapy
  drugs.AMPK, adenosine monophosphate-activated protein kinase; C-K, compound K; EGFR-TKI,
  epidermal growth factor receptor-tyrosine kinase inhibitor; mTOR mammalian target
  of rapamycin.
pmcid: PMC6887802
papertitle: Autophagy and pulmonary disease.
reftext: Shi-xia Liao, et al. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619890538.
pmc_ranked_result_index: '15692'
pathway_score: 0.928016
filename: 10.1177_1753466619890538-fig3.jpg
figtitle: Lung cancer and autophagy pathway
year: '2019'
organisms: Homo sapiens
ndex: d313680f-df0b-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6887802__10.1177_1753466619890538-fig3.html
  '@type': Dataset
  description: Lung cancer and autophagy pathway. The blue arrows show the relationships
    between autophagy and occurrence/development of lung cancer. C-K activates mTOR
    through AMPK signal pathway, inactivation of ULKI induced by mTOR increases autophagy
    and participates in the growth and migration of tumor cells. EGFR-TKI involves
    in the development of lung cancer by inhibiting autophagy levels. The yellow arrows
    show that inhibiting autophagy enhances the sensitivity of lung cancer to chemotherapy
    drugs.AMPK, adenosine monophosphate-activated protein kinase; C-K, compound K;
    EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; mTOR mammalian
    target of rapamycin.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PRKAG2
  - PRKAG3
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - ATG13
  - BECN1
  - RB1CC1
  - MAP1LC3A
  - MTOR
  - ULK1
  - lung cancer
  - tumor
genes:
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG2
  entrez: '51422'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG3
  entrez: '53632'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA1
  entrez: '5562'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA2
  entrez: '5563'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB1
  entrez: '5564'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB2
  entrez: '5565'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG1
  entrez: '5571'
- word: Atg13
  symbol: ATG13
  source: hgnc_symbol
  hgnc_symbol: ATG13
  entrez: '9776'
- word: BECN1
  symbol: BECN1
  source: hgnc_symbol
  hgnc_symbol: BECN1
  entrez: '8678'
- word: FIP200
  symbol: FIP200
  source: hgnc_alias_symbol
  hgnc_symbol: RB1CC1
  entrez: '9821'
- word: LC3
  symbol: LC3
  source: hgnc_alias_symbol
  hgnc_symbol: MAP1LC3A
  entrez: '84557'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ULK1
  symbol: ULK1
  source: hgnc_symbol
  hgnc_symbol: ULK1
  entrez: '8408'
chemicals: []
diseases:
- word: lung cancer
  source: MESH
  identifier: D008175
- word: tumor
  source: MESH
  identifier: D009369
---
